First Republic Investment Management Inc. increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 505,541 shares of the biopharmaceutical company’s stock after buying an additional 4,472 shares during the period. First Republic Investment Management Inc.’s holdings in Gilead Sciences were worth $39,032,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in GILD. Bank of New York Mellon Corp lifted its position in Gilead Sciences by 199,789.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 31,350,714 shares of the biopharmaceutical company’s stock valued at $2,420,587,000 after acquiring an additional 31,335,030 shares in the last quarter. Skandinaviska Enskilda Banken AB publ lifted its position in Gilead Sciences by 285.0% in the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 3,998,024 shares of the biopharmaceutical company’s stock valued at $308,688,000 after acquiring an additional 2,959,697 shares in the last quarter. Swedbank lifted its position in Gilead Sciences by 103.7% in the 3rd quarter. Swedbank now owns 3,906,172 shares of the biopharmaceutical company’s stock valued at $301,596,000 after acquiring an additional 1,988,987 shares in the last quarter. Natixis lifted its position in Gilead Sciences by 4,550.6% in the 2nd quarter. Natixis now owns 1,913,535 shares of the biopharmaceutical company’s stock valued at $135,555,000 after acquiring an additional 1,872,389 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in Gilead Sciences by 63.1% in the 3rd quarter. Renaissance Technologies LLC now owns 4,489,648 shares of the biopharmaceutical company’s stock valued at $346,646,000 after acquiring an additional 1,737,248 shares in the last quarter. 78.19% of the stock is currently owned by institutional investors and hedge funds.
Gilead Sciences stock opened at $69.55 on Thursday. Gilead Sciences, Inc. has a 52 week low of $64.27 and a 52 week high of $89.54. The company has a current ratio of 3.45, a quick ratio of 3.37 and a debt-to-equity ratio of 1.09. The company has a market cap of $89.97 billion, a price-to-earnings ratio of 8.13, a PEG ratio of -2.70 and a beta of 1.01.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 28th. Investors of record on Friday, December 14th will be issued a $0.57 dividend. The ex-dividend date of this dividend is Thursday, December 13th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.28%. Gilead Sciences’s dividend payout ratio (DPR) is presently 26.64%.
Several equities analysts recently weighed in on the stock. ValuEngine raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, December 1st. BidaskClub cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, November 21st. Evercore ISI reissued a “buy” rating on shares of Gilead Sciences in a research report on Wednesday, October 31st. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, November 14th. Finally, Mizuho reissued a “buy” rating and set a $94.00 target price on shares of Gilead Sciences in a research report on Friday, August 10th. Eleven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $88.63.
In related news, Director John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, November 1st. The shares were sold at an average price of $69.55, for a total value of $3,477,500.00. Following the sale, the director now owns 3,067,762 shares of the company’s stock, valued at approximately $213,362,847.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 150,000 shares of company stock worth $10,939,500 in the last ninety days. 1.30% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/12/06/first-republic-investment-management-inc-raises-stake-in-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Article: Short Selling – Explanation For Shorting Stocks
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.